8-K: 2seventy bio Announces Q4 and Full Year 2023 Results, Strategic Shift to Abecma

2seventy bio reported its Q4 and full year 2023 financial results, highlighted by a strategic realignment focusing on Abecma and an upcoming FDA review for label expansion.

Summary

• 2seventy bio announced its fourth quarter and full year 2023 financial results, alongside a strategic shift to focus on its Abecma therapy.
• The company reported $56 million in U.S. Abecma revenue for Q4 2023 and $358 million for the full year, shared equally with Bristol Myers Squibb.
• Total revenue for Q4 2023 was $10.7 million, compared to $56.2 million in Q4 2022, while full year revenue was $100.4 million, up from $91.5 million in 2022.
• The company's net loss for Q4 2023 was $56.8 million, compared to a $23.1 million loss in Q4 2022, and the full year net loss was $217.6 million, compared to $254.2 million in 2022.
• 2seventy bio is selling its R&D pipeline to Regeneron, expected to close in the first half of 2024, which is projected to save $150 million in 2024 and $200 million in 2025.
• The company ended the quarter with $221.8 million in cash, cash equivalents, and marketable securities, extending its cash runway beyond 2027.
• An FDA advisory committee meeting is scheduled for March 15, 2024, to review Abecma's application for use in earlier lines of multiple myeloma treatment.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the strategic shift and potential label expansion for Abecma are positive, the significant revenue decline and net losses are concerning. The sentiment is neutral to slightly negative due to the financial results.

Positives

• The strategic realignment to focus on Abecma is expected to significantly reduce costs.
• The company has a strong cash position, extending its runway beyond 2027.
• The KarMMa-3 study showed a significant improvement in progression-free survival with Abecma compared to standard regimens.
• The KarMMa-2 cohort 2c study demonstrated a high complete response rate with Abecma in newly diagnosed multiple myeloma.
• The upcoming ODAC meeting and potential label expansion for Abecma could drive future growth.

Negatives

• Abecma sales declined in the fourth quarter due to competition from other BCMA-targeted therapies.
• The company experienced a significant net loss for both the fourth quarter and the full year 2023.
• Total revenue decreased significantly in Q4 2023 compared to Q4 2022.
• The company is incurring one-time cash restructuring costs of approximately $8 10 million.

Risks

• The company faces competition from other BCMA-targeted therapies, which could impact Abecma sales.
• The FDA may not approve the supplemental Biologics License Application for Abecma, which would limit its market potential.
• The strategic realignment and asset sale may not be as successful as anticipated and could cause disruptions.
• The company may not be able to manage its operating expenses or cash use for operations effectively.
• There are risks associated with the manufacturing and commercialization of Abecma.

Future Outlook

The company anticipates potential label expansion for Abecma following the ODAC meeting and expects the asset sale to Regeneron to close in the first half of 2024. They also expect to have extended cash runway beyond 2027.

Management Comments

• Chip Baird, incoming CEO, stated that 2seventy has made significant changes to its business and cost structure to optimize the value of Abecma.
• Management expressed confidence in the outcome of the ODAC meeting and the potential for Abecma's approval in the third-line setting.
• Management believes that the expanded label and ongoing commercial execution, along with the KarMMa-9 study, will solidify Abecma's role as an important treatment option.

Industry Context

This announcement reflects the competitive landscape in the multiple myeloma treatment space, where companies are vying for market share with novel therapies. The strategic shift by 2seventy bio to focus on Abecma highlights the importance of targeted therapies and the need to adapt to market dynamics. The collaboration with Bristol Myers Squibb is a common model in the industry for developing and commercializing complex therapies.

Comparison to Industry Standards

• The reported Abecma revenue of $358 million for the full year is a significant figure in the CAR T-cell therapy market, but it is important to compare this to other similar therapies such as Johnson & Johnson's Carvykti, which has also shown strong sales growth.
• The 51% reduction in risk of disease progression or death in the KarMMa-3 study is a positive result, but it needs to be compared to the results of other CAR T-cell therapies and novel treatments in multiple myeloma.
• The strategic realignment and asset sale are a significant move, and it is important to compare this to other companies that have undergone similar restructurings to assess the potential impact on the company's future performance.
• The cash runway extended beyond 2027 is a positive sign, but it is important to compare this to the cash positions of other biotech companies in the same stage of development.

Related Party Transactions

• The document mentions a collaborative arrangement with Bristol Myers Squibb for the development and commercialization of Abecma, where profits and losses are shared equally.

Stakeholder Impact

• Shareholders may be impacted by the strategic realignment and asset sale, as well as the financial results.
• Employees may be impacted by the restructuring and potential job losses.
• Patients may benefit from the potential label expansion of Abecma.
• Suppliers and creditors may be impacted by the company's financial performance and strategic changes.

Next Steps

• The company will await the FDA's decision on the sBLA for Abecma following the ODAC meeting on March 15, 2024.
• The company expects to close the asset sale to Regeneron in the first half of 2024.
• The company will continue to focus on the commercialization of Abecma and the ongoing KarMMa-9 study.

Key Dates

Keywords

Abecma, Multiple Myeloma, Cell Therapy, Immunotherapy, FDA, Oncologic Drugs Advisory Committee, KarMMa-3, KarMMa-2, Regeneron, Strategic Realignment, Asset Sale, Bristol Myers Squibb